Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoRay
NCT03872778Phase 2Completed
- Sponsor
- Advanced Accelerator Applications
- Start
- Jul 2019
- Primary completion
- Jan 2025
- Modality
- Peptides
- Countries
- 6
01
Overview
Phase 2, open-label trial of neobomb1 in solid tumor (8 cohorts), sponsored by Advanced Accelerator Applications. Primary endpoints: Dose Limiting Toxicities at 42 days, Maximum Tolerated Dose / Recommended Phase 2 Dose at 18 months and 4 more. Started Jul 2019; status: completed.
02
Drugs
neobomb1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03872778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872778.